Evidence map›Paper›PMID 32095544›Full record

ReviewTechnical innovations & patient support in radiation oncology2019

Proton therapy- the modality of choice for future radiation therapy management of Prostate Cancer?

Sophie Mangan, Michelle Leech

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Technical innovations & patient support in radiation oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. A scoping review of patient selection methods for proton therapy.Journal of medical radiation sciences · 2022
    Article
  2. Immunomodulatory Effects of Radiotherapy.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sophie ManganApplied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin, Dublin 2, Ireland.
Michelle LeechApplied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin, Dublin 2, Ireland.
Trinity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProton Therapy (PR) is an emerging treatment for prostate cancer (Pca) patients. However, limited and conflicting data exists regarding its ability to result in fewer bladder and rectal toxicities compared to Photon Therapy (PT), as well as its cost efficiency and plan robustness. MATERIALS AND

methodsAn electronic literature search was performed to acquire eligible studies published between 2007 and 2018. Studies comparing bladder and rectal dosimetry or Gastrointestinal (GI) and Genitourinary (GU) toxicities between PR and PT, the plan robustness of PR relative to motion and its cost efficiency for Pca patients were assessed.

results28 studies were eligible for inclusion in this review. PR resulted in improved bladder and rectal dosimetry but did not manifest as improved GI/GU toxicities clinically compared to PT. PR plans were considered robust when specific corrections, techniques, positioning or immobilisation devices were applied. PR is not cost effective for intermediate risk Pca patients; however PR may be cost effective for younger or high risk Pca patients.

conclusionPR offers improved bladder and rectal dosimetry compared to PT but this does not specifically translate to improved GI/GU toxicities clinically. The robustness of PR plans is acceptable under specific conditions. PR is not cost effective for all Pca patients.

Indexed as

3DC-PR, 3D Conformal- Proton TherapyBT, BrachytherapyCTCAE, Common Terminology Criteria Adverse EffectsCT, Computed TomographyEPIC, Expanded Prostate Cancer Index CompositeGI, GastrointestinalGU, GenitourinaryHT, Helical TomographyIGRT, Image Guidance Radiation TherapyIMPR, Intensity Modulated Proton TherapyIMRT, Intensity Modulated Radiation Therapyint/HR, intermediate/High riskIPSS, International Prostate Symptom ScaleITV, Internal Target VolumeLR, Low RiskMFO-IMPR, Multi Field Optimisation-Intensity Modulated Proton TherapyPBS, Pencil Beam ScanningPhoton therapyProstate cancerProton therapyPR, Proton TherapyPT, Photon TherapyQALY, Quality-Adjusted Life YearRA, Rapid ArcRBE, Radiobiological EffectivenessRTOG, Radiation Therapy Oncology GroupSBRT, Stereotactic Body RadiationSFUD, Single Field Uniform-DoseSW, Sliding WindowUSPT, Uniform Scanning Proton TherapyUS, Uniform ScanningVMAT, Volumetric Modulated Arc Therapy

Identifiers

PMID32095544
PMCPMC7033803
OpenAlexW2979535820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.